Duloxetine Capsule, Delayed Release
Product Images NDC 68788-8782

This is a chart displaying the proportion of patients experiencing a relapse over time in a study comparing a placebo group with a group taking duloxetine. The data is presented in a graph showing the time from randomization to relapse in days, using the Kaplan-Meier estimator method.*

This text provides information on the proportion of patients experiencing relapse over different time intervals under the treatment conditions of Placebo and Duloxetine. The data presented is likely derived from a study or clinical trial and includes the duration in days from randomization to relapse using the Kaplan-Meier estimator method.*

This text provides information on the percentage of patients improved with different treatment options such as Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and Placebo. It also mentions the percent improvement in pain from baseline.*

Percentage of Patients Improved in terms of pain relief after taking Duloxetine 60 mg BID, Duloxetine 60 mg QD, and Placebo.*

This is a chart displaying the percentage of patients improved in pain from baseline for different dosage regimens of Duloxetine and Placebo. It shows the percentage of improvement at various levels of pain relief, including percentages for each treatment option (Duloxetine 60 mg Twice Daily, Duloxetine 60 mg Once Daily, and Placebo).*

This text provides information on the percentage of patients improved with different doses of medication (Duloxetine) compared to a placebo. It also includes a scale showing percent improvement in pain from baseline.*

This is a representation of Figure 7 showing the percentage of pediatric patients aged 13 to 17 years old with Juvenile Fibromyalgia Syndrome and their levels of pain relief at week 12 in Study FM-4. The graph compares the percentage of patients improved using Duloxetine 60mg once daily versus Placebo. Pain relief was measured using the Brief Pain Inventory - Modified Short Form: Adolescent Version Average Pain Score. Duloxetine-treated patients started with 30mg once daily for 1 week and then increased to 60mg once daily for 12 weeks as tolerated.*

This text provides data on the percentage of patients who saw improvement in pain levels after taking either a placebo or Duloxetine at 60/120 mg once daily. The chart indicates the percent improvement in pain from baseline as well.*

This text shows the percentage of patients improved based on a comparison between a placebo and duloxetine 60 mg. It indicates a 100% improvement with duloxetine 60 mg compared to the placebo. It also includes a graph showing the percent improvement in pain from the baseline using the Last Observation Carried Forward (LOCF) method.*

The text provides information on the percentage of patients improved with Duloxetine (60/120 mg once daily) in comparison to placebo. It shows a graph depicting percent improvement in pain from baseline.*

This text provides information about Duloxetine Delayed-Release Capsules USP 40mg, a generic version of Cymbalta. Each capsule contains 44.9mg of Duloxetine HCI USP equivalent to 40mg Duloxetine. The packaging details the expiry date, lot number, batch number, and manufacturer (Lupin Limited). There are specific storage instructions at 25°C (77°F) with permitted excursions between 15°-30°C (59°-86°F). The warning advises keeping the medication away from children and that it should only be used as prescribed (Rx only). The capsule is white and imprinted with LU H25. Additionally, there is a caution about federal law prohibiting the transfer of the drug to anyone other than the prescribed patient.*